GenMark's Q4 Revenues Spike 157 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GenMark Diagnostics said after the close of the market on Thursday that its fourth-quarter revenues more than doubled year over year, led by a 156 percent spike in reagent sales.

For the three months ended Dec. 31, 2010, the Carlsbad, Calif.-based firm posted $787,482 in revenues, up 157 percent from $306,410 a year ago and above a Wall Street forecast of $690,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.

Sponsored by
Agilent Technologies

This online seminar will discuss a metagenomic assay to identify viruses and other pathogenic microorganisms in human tumor samples, with the aim of gaining a more comprehensive understanding of the role of the microbiome in cancer development and treatment.